
|Videos|February 27, 2017
Medicare Part D and Oncology
Author(s)Lauren Santye, Assistant Editor
Marc O'Connor, COO and chief strategy officer at Curant Health, discusses how the shift to Medicare Part D could impact patients undergoing treatment for cancer.
Advertisement
Marc O'Connor, COO and chief strategy officer at Curant Health, discusses how the shift to Medicare Part D could impact patients undergoing treatment for cancer.
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
FDA, ASH Experts Review Newly Approved Therapies in Hemophilia
2
How a New Generation of CAR T-Cell Therapies Could Reduce the Risk of Rejection
3
Pharmacist Strategies for Managing Comorbid Depression and Diabetes
4
A Cup of Coffee or Life-Saving Drugs: Shifting Decision-Making Practices in Health Care
5




















































































































































































































